RWRussell D. Wolfinger

Russell D. Wolfinger

*This is an algorithmically generated author record based on publicly available information.

Russell D. Wolfinger has a total of 97 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    CDISC Enables Efficient Streamlining of Clinical Trial Safety Evaluation

    by Wenjun Bao, Geoffrey Mann, Thomas J Pedersen, Rebecca Lyzinski, Anisa Scott, Andrew J Foglia, John Cromer, Meichen Dong, Nora Varga, Sam Gardner, et al.

    The use of standardized data formats has increasingly facilitated both the submission of clinical trial data by pharmaceutical companies and its review by regulatory agencies. The Clinical Data Integration Standards Consortium (CDISC) format has become the de facto worldwide standard for clinical trial data submissions and review. CDISC data are captured and organized in defined datasets, or domains, with predefined variable names and attributes. As a result, researchers and reviewers have a consistent, repeatable, and rapid way to load, review, and analyze data. The benefits provided by this standardization have culminated in the development of software that intuitively utilizes CDISC structures to quickly import and analyze the data as well as summarize the results for scientists and clinicians in a collection of readable and easy-to-understand reports. In this paper, we will show how CDISC datasets with their required domains and respective variables can be utilized by JMP® Clinical to create clinical trial analysis reports easily and quickly with interactive graphs and tables for use in FDA New Drug Applications and Clinical Reviews. These reports are also ready for inclusion in regulatory submissions such as regulatory documents and clinical study reports to improve reviewability, interpretability, and efficiency of regulatory submission and review.

  • Open Access

    Two approaches for estimating the lower limit of quantitation (LLOQ) of microRNA levels assayed as exploratory biomarkers by RT-qPCR

    by Russell D. Wolfinger, Sudheer Beedanagari, Eric Boitier, Tao Chen, Philippe Couttet, Heidrun Ellinger-Ziegelbauer, Gregory Guillemain, Claire Mariet, Peter Mouritzen, Raegan O’lone, et al.

    Circulating microRNAs are undergoing exploratory use as safety biomarkers in drug development. Reverse transcription quantitative polymerase chain reaction (RT-qPCR) is one common approach used to quantitate levels of microRNAs in samples that includes the use of a standard curve of calibrators fit to a regression model. Guidelines are needed for setting assay quantitation thresholds that are appropriate for this method and to biomarker pre-validation. In this report, we develop two workflows for determining a lower limit of quantitation (LLOQ) for RT-qPCR assays of microRNAs in exploratory studies. One workflow is based on an error threshold calculated by a logistic model of the calibration curve data. The second workflow is based on a threshold set by the sample blank, which is the no template control for RT-qPCR. The two workflows are used to set lower thresholds of reportable microRNA levels for an example dataset in which miR-208a levels in biofluids are quantitated in a cardiac injury model. LLOQ thresholds set by either workflow are effective in filtering out microRNA values with large uncertainty estimates. Two workflows for LLOQ determinations are presented in this report that provide methods that are easy to implement in investigational studies of microRNA safety biomarkers and offer choices in levels of conservatism in setting lower limits of acceptable values that facilitate interpretation of results.


  • Open Access

    A cancer pharmacogenomic screen powering crowd-sourced advancement of drug combination prediction

    by Michael Patrick Menden, Dennis Wang, Yuanfang Guan, Michael Mason, Bence Szalai, Krishna C Bulusu, Thomas Yu, Jaewoo Kang, Minji Jeon, Russ Wolfinger, et al.

    The effectiveness of most cancer targeted therapies is short lived since tumors evolve and develop resistance. Combinations of drugs offer the potential to overcome resistance, however the number of possible combinations is vast necessitating data-driven approaches to find optimal treatments tailored to a patient’s tumor. AstraZeneca carried out 11,576 experiments on 910 drug combinations across 85 cancer cell lines, recapitulating in vivo response profiles. These data, the largest openly available screen, were hosted by DREAM alongside deep molecular characterization from the Sanger Institute for a Challenge to computationally predict synergistic drug pairs and associated biomarkers. 160 teams participated to provide the most comprehensive methodological development and subsequent benchmarking to date. Winning methods incorporated prior knowledge of putative drug target interactions. For >60% of drug combinations synergy was reproducibly predicted with an accuracy matching biological replicate experiments, however 20% of drug combinations were poorly predicted by all methods. Genomic rationale for synergy predictions were identified, including antagonism unique to combined PIK3CB/D inhibition with the ADAM17 inhibitor where synergy is seen with other PI3K pathway inhibitors. All data, methods and code are freely available as a resource to the community.


  • Open Access

    Global transcriptome analysis of Clostridium thermocellum ATCC 27405 during growth on dilute acid pretreated Populus and switchgrass

    by Charlotte M Wilson, Miguel Rodriguez, Courtney M Johnson, Stanton L Martin, Tzu Ming Chu, Russ D Wolfinger, Loren J Hauser, Miriam L Land, Dawn M Klingeman, Mustafa H Syed, et al.

    Background: The thermophilic anaerobeClostridium thermocellumis a candidate consolidated bioprocessing (CBP) biocatalyst for cellulosic ethanol production. The aim of this study was to investigateC. thermocellumgenes required to ferment biomass substrates and to conduct a robust comparison of DNA microarray and RNA sequencing (RNA-seq) analytical platforms.Results: C. thermocellumATCC 27405 fermentations were conducted with a 5 g/L solid substrate loading of either pretreated switchgrass orPopulus. Quantitative saccharification and inductively coupled plasma emission spectroscopy (ICP-ES) for elemental analysis revealed composition differences between biomass substrates, which may have influenced growth and transcriptomic profiles. High quality RNA was prepared forC. thermocellumgrown on solid substrates and transcriptome profiles were obtained for two time points during active growth (12 hours and 37 hours postinoculation). A comparison of two transcriptomic analytical techniques, microarray and RNA-seq, was performed and the data analyzed for statistical significance. Large expression differences for cellulosomal genes were not observed. We updated gene predictions for the strain and a small novel gene, Cthe_3383, with a putative AgrD peptide quorum sensing function was among the most highly expressed genes. RNA-seq data also supported different small regulatory RNA predictions over others. The DNA microarray gave a greater number (2,351) of significant genes relative to RNA-seq (280 genes when normalized by the kernel density mean of M component (KDMM) method) in an analysis of variance (ANOVA) testing method with a 5% false discovery rate (FDR). When a 2-fold difference in expression threshold was applied, 73 genes were significantly differentially expressed in common between the two techniques. Sulfate and phosphate uptake/utilization genes, along with genes for a putative efflux pump system were some of the most differentially regulated transcripts when profiles forC. thermocellumgrown on either pretreated switchgrass orPopuluswere compared.Conclusions: Our results suggest that a high degree of agreement in differential gene expression measurements between transcriptomic platforms is possible, but choosing an appropriate normalization regime is essential.


  • Open Access

    Kernel density weighted loess normalization improves the performance of detection within asymmetrical data

    by Wen-Ping Hsieh, Tzu-Ming Chu, Yu-Min Lin, Russell D Wolfinger

    Normalization of gene expression data has been studied for many years and various strategies have been formulated to deal with various types of data. Most normalization algorithms rely on the assumption that the number of up-regulated genes and the number of down-regulated genes are roughly the same. However, the well-known Golden Spike experiment presents a unique situation in which differentially regulated genes are biased toward one direction, thereby challenging the conclusions of previous bench mark studies.


  • A Unified Mixed Effects Model for Gene Set Analysis of Time Course Microarray Experiments

    by Lily Wang, Xi Chen, Russell D Wolfinger, Jeffrey L Franklin, Robert J Coffey, Bing Zhang

    Methods for gene set analysis test for coordinated changes of a group of genes involved in the same biological process or molecular pathway. Higher statistical power is gained for gene set analysis by combining weak signals from a number of individual genes in each group. Although many gene set analysis methods have been proposed for microarray experiments with two groups, few can be applied to time course experiments. We propose a unified statistical model for analyzing time course experiments at the gene set level using random coefficient models, which fall into the more general class of mixed effects models. These models include a systematic component that models the mean trajectory for the group of genes, and a random component (the random coefficients) that models how each gene's trajectory varies about the mean trajectory.We show that the proposed model (1) outperforms currently available methods at discriminating gene sets differentially changed over time from null gene sets; (2) provides more stable results that are less affected by sampling variations; (3) models dependency among genes adequately and preserves type I error rate; and (4) allows for gene ranking based on predicted values of the random effects. We describe simulation studies using gene expression data with "real life" correlations and we demonstrate the proposed random coefficient model using a mouse colon development time course dataset. The agreement between results of the proposed random coefficient model and the previous reports for this proof-of-concept trial further validates this methodology, which provides a unified statistical model for systems analysis of microarray experiments with complex experimental designs when re-sampling based methods are difficult to apply.


  • Open Access

    Sources of variation in baseline gene expression levels from toxicogenomics study control animals across multiple laboratories

    by Michael J Boedigheimer, Russell D Wolfinger, Michael B Bass, Pierre R Bushel, Jeff W Chou, Matthew Cooper, J Christopher Corton, Jennifer Fostel, Susan Hester, Janice S Lee, et al.

    Background: The use of gene expression profiling in both clinical and laboratory settings would be enhanced by better characterization of variance due to individual, environmental, and technical factors. Meta-analysis of microarray data from untreated or vehicle-treated animals within the control arm of toxicogenomics studies could yield useful information on baseline fluctuations in gene expression, although control animal data has not been available on a scale and in a form best served for data-mining. Results: A dataset of control animal microarray expression data was assembled by a working group of the Health and Environmental Sciences Institute's Technical Committee on the Application of Genomics in Mechanism Based Risk Assessment in order to provide a public resource for assessments of variability in baseline gene expression. Data from over 500 Affymetrix microarrays from control rat liver and kidney were collected from 16 different institutions. Thirty-five biological and technical factors were obtained for each animal, describing a wide range of study characteristics, and a subset were evaluated in detail for their contribution to total variability using multivariate statistical and graphical techniques. Conclusion: The study factors that emerged as key sources of variability included gender, organ section, strain, and fasting state. These and other study factors were identified as key descriptors that should be included in the minimal information about a toxicogenomics study needed for interpretation of results by an independent source. Genes that are the most and least variable, gender-selective, or altered by fasting were also identified and functionally categorized. Better characterization of gene expression variability in control animals will aid in the design of toxicogenomics studies and in the interpretation of their results.


  • Statistical Analysis of Relative Labeled Mass Spectrometry Data from Complex Samples Using ANOVA

    by Ann L. Oberg, Douglas W. Mahoney, Jeanette E. Eckel-Passow, Christopher J. Malone, Russell D. Wolfinger, Elizabeth G. Hill, Leslie T. Cooper, Oyere K. Onuma, Craig Spiro, Terry M. Therneau, et al.

    Statistical tools enable unified analysis of data from multiple global proteomic experiments, producing unbiased estimates of normalization terms despite the missing data problem inherent in these studies. The modeling approach, implementation, and useful visualization tools are demonstrated via a case study of complex biological samples assessed using the iTRAQ relative labeling protocol.